The earlier guide and its original links remain below.
A READING COMPANION / JOHN GRIFFIN, MD
Beyond the first prescription
GLP-1 medicines, metabolic health, and the connection to sleep.
A full article from the October 25 edition, adapted after checking its primary abstract, plus an explanatory article on the randomized sleep-apnea evidence. Different designs. Different questions.
2 November 2026 · Online version 1.3 · Mazdutide reading added; earlier articles and the October 30 PDF retain their dates
Mazdutide: weight loss and the ability to stay with treatment
Original conceptual illustration. The two paths represent benefit and tolerability; they are not study data.
A weight-loss result becomes more useful when we can see what it took to achieve it. The Arising’s November 2 full article on mazdutide places the size of the benefit beside the difficulty some participants had continuing treatment.
What the trial tested
Mazdutide activates GLP-1 and glucagon receptors. A double-blind, randomized phase 2 trial at 24 US centers enrolled 179 adults with overweight or obesity, without type 2 diabetes. Participants received weekly mazdutide at one of three dose schedules or placebo for 48 weeks. The primary comparison was body-weight change at 32 weeks. The paper appeared online August 21, 2026 and in the November journal issue; this is a fresh reading of that evidence, not a trial announced today.
Two numbers belong together
At 32 weeks, estimated mean weight change in the 16 mg group was −18.1%, compared with −0.9% for placebo. In that highest-dose group, 20% discontinued study treatment because of adverse effects, mainly gastrointestinal problems. The weight estimate and discontinuation percentage describe different outcomes and time frames: the latter is reported across the trial, not specifically at week 32. Neither number cancels the other.
What the estimate assumes
The primary analysis used a hypothetical efficacy estimand. That is an estimate under specified treatment assumptions, not the average result everyone who starts the medicine should expect in ordinary care. How missing observations and treatment interruptions are handled can change the question an analysis answers. The full statistical plan and participant-level data were not independently reanalyzed for this reading.
A phase 2 result has boundaries
The comparator was placebo, not another active obesity medicine. These results do not establish superiority to semaglutide, tirzepatide or retatrutide. The trial does not demonstrate longer life, fewer cardiovascular events or preserved muscle function. Its population also cannot stand in for every older person or everyone with diabetes. Eli Lilly funded the study; a sponsor-funded trial is not independent replication.
The question worth carrying forward
What can people sustain, and what does treatment let them do? Our GLP-1 collection follows treatment continuity, breathing during sleep, skeletal health and emerging medicines as distinct questions. Weight change matters, but so do symptoms, function, access and treatment burden. This study supplies one part of that picture. It does not supply a personal prescribing decision.
Sources and review limits
Primary PubMed abstract and trial-registry design, dates and endpoints checked November 2, 2026. Registry: completed, 179 participants, last update posted April 21, 2026; posted results indicated, but complete results tables were not appraised here. Publisher search retrieval corroborated the abstract and August 21 online date; full publisher page returned 403. Full text, supplements, complete harms and author-level conflicts were not appraised. No claim of regulatory availability is made.
Source: The_Arising_Health_Intelligence_2026-11-02.html · v1.0 · A04 · The next weight-loss drugs are moving quickly. Tolerability still sets the pace.. Claim AR-20261102-MAZ-01.
Educational writing, not individual medical advice. Alive. Awake. Aware.
THE ARISING · OCTOBER 30 UPDATE · SOURCE ISSUE OCTOBER 29
Retatrutide: greater weight loss, more treatment withdrawals
The next generation of metabolic medicines will be judged by benefits people can sustain. The Arising’s October 29 full article examined retatrutide, an investigational medicine acting on GIP, GLP-1 and glucagon receptors. This October 30 update checks Lilly’s original October 28 announcement and the trial registry.
What Lilly reported
In an 80-week randomized, open-label comparison with Ozempic 2 mg in adults with type 2 diabetes, the 12 mg retatrutide group had average weight loss of 20.9%, versus 9.4%. A1C fell by 2.2 versus 1.8 percentage points. These are company-reported topline results, not an independently replicated finding or a full peer-reviewed paper.
The tradeoff belongs beside the benefit
Treatment discontinuation because of adverse events was 7.9% with retatrutide 12 mg versus 2.7% with Ozempic. Common adverse events included gastrointestinal symptoms. A larger average benefit does not tell us whether a particular person will tolerate or benefit from treatment.
How the analysis was framed
The reported efficacy estimate assumes participants remained on treatment without additional glucose-lowering medication. It should not be read as the expected result for everyone who starts treatment. The original announcement supplies more detail than the secondary article: it reports 1,298 participants. The older September 28 registry still lists an estimated 1,250 and has no posted results. Those dated records are not interchangeable.
Where this fits in The Arising
Our GLP-1 collection follows glucose control, sleep, bone health and the ability to stay active. This trial addresses weight and A1C; it does not establish longer life, preserved muscle or fewer heart attacks. Those outcomes require their own evidence. Retatrutide remains investigational in Lilly’s announcement. This article is education, not advice to obtain or change a medicine.
What comes next
A full publication should clarify missing data, treatment-policy results, serious harms and subgroup differences. Sustained health and daily function remain the questions worth following alongside weight loss.
GLP-1 medicines and bone density: what eight trials can tell us
Some trials found lower bone density. The evidence remains too limited to establish the effects of the drug class or the risk of fractures.
Source edition: October 27, 2026, story 3, pages 11–12. Adapted October 28 after checking the primary abstract. Review published October 23, 2026.
Weight loss is one outcome of treatment. Bone health is another. A systematic review in Archives of Osteoporosis examined eight randomized trials involving 493 adults with overweight or obesity. Its conclusion is cautious: the available studies are too small and too different to determine the skeletal effects of GLP-1 medicines in this population.
What the review examined
The researchers searched studies published from January 2015 through July 2026. Eligible trials lasted at least 12 weeks, compared a GLP-1 medicine with placebo or another diabetes treatment, and measured bone mineral density using DXA. Five of the eight trials enrolled people with type 2 diabetes. The review reported each medicine separately rather than combining them into one class-wide estimate.
Three trials were rated at low risk of bias; five raised some concerns. No medicine had more than one low-risk trial supporting it. The certainty of evidence was very low for every agent.
Where bone-density reductions appeared
The single semaglutide trial, with 64 participants, reported lower lumbar-spine and whole-body bone density compared with placebo, alongside greater weight loss and a rise in a marker of bone breakdown. A trial of liraglutide at 3.0 mg daily also reported lower spine and hip bone density. A separate trial of liraglutide at 1.8 mg did not find material changes at the measured sites. Exenatide findings were inconsistent.
The two trials with the largest weight loss both reported bone-density reductions. That pattern deserves further investigation. It does not establish whether the changes came from weight loss, a direct drug effect, or a combination, and it cannot be transferred automatically to every GLP-1 medicine.
Bone density is not a fracture outcome
The review does not establish an increased risk of fractures. Its authors call for larger, medicine-specific trials that measure fractures. A broader 2026 review, using different eligibility criteria and analyses, reported no significant bone effects in its most-adjusted pooled analyses. These reviews should not be treated as interchangeable: their populations, study designs and synthesis methods differ.
For readers following longevity research, this is a reason to examine physical function and skeletal outcomes alongside weight and metabolic measures. It is not a reason to assume that a treatment’s benefits have disappeared, or to change an individual prescription on the basis of a headline.
This adaptation uses the primary abstracts. Full texts, supplements, individual trial reports, complete harms, funding and conflict disclosures were not appraised. The newsletter’s “1 trials” display is not reproduced: the primary review reports eight trials. This online article is additional to the four-page October 25 PDF v1.1; that downloadable edition has not been changed.
What a study of older adults can—and cannot—tell us about sustained GLP-1 use.
Study publication: October 22, 2026 · Reading edition: October 25, 2026
A medication’s promise is tested in ordinary life: whether someone can obtain it, tolerate it and keep using it. Today’s GLP-1 story starts there. In a large Israeli health-record study, older adults who collected more prescriptions had better weight and blood-sugar outcomes than those who collected only one or two. The result is worth following. It is not proof that continuing a drug caused every difference.
What the researchers compared
Zaritsky and colleagues studied records from Clalit Health Services for 13,387 adults aged 65 or older. Everyone had obesity and no diabetes at the start, and all had paired body-mass-index measurements. Sixty-nine percent were women. The researchers defined minimal exposure as one or two prescription dispensations and sustained exposure as three or more.
This definition matters. Three fills do not establish years of continuous treatment, an exact dose or actual medication use. The comparison was between two groups who had started treatment, not between people randomly assigned to a GLP-1 medicine and a placebo.
The findings
The primary outcome was improvement to a lower BMI category. That occurred in 55% of the sustained-exposure group and 30% of the minimal-exposure group. Blood-sugar categories also improved more often in the subset with paired HbA1c measurements, and diagnosed diabetes was less frequent in the sustained group.
The main statistical model adjusted for age, sex, socioeconomic status and other medical conditions. The study was published online in Diabetes, Obesity and Metabolism on October 22, 2026. Our appraisal here is limited to the primary abstract. It does not supply a follow-up duration, so these findings should not be turned into a fixed annual prevention estimate.
The question behind the association
People who continue treatment can differ from those who stop. Tolerability, access, other illness and health habits may influence both prescription fills and outcomes. Adjustment cannot remove every such difference. The authors explicitly describe observed changes after treatment initiation, rather than a proven causal treatment effect.
For longevity, the useful question reaches beyond a number on a scale: what changes in health and daily function, for whom, for how long, and with what trade-offs? This study addresses metabolic outcomes in a particular older population. It did not establish lifespan extension, measure every potential harm or answer whether one individual should take a medicine.
The next step is to connect these real-world patterns with randomized evidence and clearer information on duration, discontinuation and function. The possibility is substantial; the conclusion should remain the size of the evidence.
A 2024 randomized trial offers context for the newer GLP-1 headlines.
Study publication: 2024 (October 3 journal issue) · Reading edition: October 25, 2026
Sleep apnea makes an important connection between metabolic health and the night. But a connection is not enough: we need to know whether a particular treatment changes a meaningful outcome in a defined group of people. The SURMOUNT-OSA trials provide a more direct test than an observational headline.
Two trials, a specific population
The researchers ran two phase 3, double-blind randomized trials in adults with obesity and moderate-to-severe obstructive sleep apnea. One trial enrolled people not receiving positive-airway-pressure treatment at baseline; the other enrolled people who were receiving it. Participants received tirzepatide or placebo for 52 weeks. This is established 2024 evidence, revisited for context, not a newly completed October 2026 trial.
The primary measure was the apnea-hypopnea index, or AHI: the number of breathing interruptions or reductions per hour of sleep. It describes the sleep disorder. It is not a measurement of lifespan or proof that a future heart attack was prevented.
What changed
In the first trial, AHI fell by 25.3 events per hour with tirzepatide and 5.3 with placebo. The estimated between-group difference was 20.0 fewer events per hour, with a 95% confidence interval of 14.2 to 25.8 fewer. In the second trial, the corresponding difference was 23.8 fewer events per hour, with a 95% confidence interval of 17.9 to 29.6 fewer.
The primary abstract also reports improvements in body weight, hypoxic burden, blood pressure and patient-reported sleep outcomes. Gastrointestinal adverse events were the most frequent side effects and were mostly mild to moderate. Eli Lilly funded the trials. These findings concern tirzepatide in the studied population; they do not automatically establish an identical effect for every GLP-1 medicine.
What the result does not settle
The trial does not establish that all sleep apnea disappears with weight loss or that prescribed airway-pressure treatment can be stopped. It also does not separate every contribution of weight loss from other possible pathways. Long-term outcomes beyond the trial and decisions for an individual require additional evidence and clinical assessment.
Today’s newsletter also describes conference reports about GLP-1 medicines and sleep apnea. Those reports raise useful questions, but their numerical claims are not reproduced here because their underlying abstracts have not been checked for this booklet. Randomized results, retrospective associations and conference reporting deserve different levels of confidence.
This is why the sleep collection and the metabolic story belong beside one another. Breathing, sleep, weight and function can be related while remaining distinct outcomes. Following the connections should make our questions more precise.
The GLP-1 cohort and SURMOUNT-OSA primary PubMed abstracts were checked October 25. Full texts, supplements and a comprehensive correction search were not appraised. The 2026 conference-derived percentages are held rather than promoted. This is not a systematic review.
Design update · October 25, 2026: celestial artwork and Arising branding replace the botanical treatment. Scientific text and evidence-review dates are unchanged. Illustration depicts an imagined observatory.
THE CONNECTED READING COLLECTION
Forty-eight subjects. A wider conversation.
The expanded physician-review collection connects each booklet to related reading and the Atlas. Access follows the shared Atlas settings.
